61 related articles for article (PubMed ID: 9203849)
1. Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates.
Bae KT; Piwnica-Worms D
Q J Nucl Med; 1997 Jun; 41(2):101-10. PubMed ID: 9203849
[TBL] [Abstract][Full Text] [Related]
2. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
Crankshaw CL; Marmion M; Luker GD; Rao V; Dahlheimer J; Burleigh BD; Webb E; Deutsch KF; Piwnica-Worms D
J Nucl Med; 1998 Jan; 39(1):77-86. PubMed ID: 9443741
[TBL] [Abstract][Full Text] [Related]
3. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
[TBL] [Abstract][Full Text] [Related]
4. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
Piwnica-Worms D; Chiu ML; Budding M; Kronauge JF; Kramer RA; Croop JM
Cancer Res; 1993 Mar; 53(5):977-84. PubMed ID: 8094997
[TBL] [Abstract][Full Text] [Related]
5. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi.
Rao VV; Chiu ML; Kronauge JF; Piwnica-Worms D
J Nucl Med; 1994 Mar; 35(3):510-5. PubMed ID: 7906729
[TBL] [Abstract][Full Text] [Related]
6. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
[TBL] [Abstract][Full Text] [Related]
7. Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein.
Ballinger JR
Cancer Biother Radiopharm; 2001 Feb; 16(1):1-7. PubMed ID: 11279792
[No Abstract] [Full Text] [Related]
8. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
[TBL] [Abstract][Full Text] [Related]
9. In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein.
Hendrikse NH; Kuipers F; Meijer C; Havinga R; Bijleveld CM; van der Graaf WT; Vaalburg W; de Vries EG
Cancer Chemother Pharmacol; 2004 Aug; 54(2):131-8. PubMed ID: 15118837
[TBL] [Abstract][Full Text] [Related]
10. Clinical imaging of multidrug resistance in cancer.
Del Vecchio S; Ciarmiello A; Salvatore M
Q J Nucl Med; 1999 Jun; 43(2):125-31. PubMed ID: 10429507
[TBL] [Abstract][Full Text] [Related]
11. In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors.
Muzzammil T; Moore MJ; Ballinger JR
Cancer Biother Radiopharm; 2000 Aug; 15(4):339-46. PubMed ID: 11041018
[TBL] [Abstract][Full Text] [Related]
12. Scintigraphic detection of multidrug resistance in cancer.
Del Vecchio S; Ciarmiello A; Salvatore M
Cancer Biother Radiopharm; 2000 Aug; 15(4):327-37. PubMed ID: 11041017
[TBL] [Abstract][Full Text] [Related]
13. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.
Wong M; Evans S; Rivory LP; Hoskins JM; Mann GJ; Farlow D; Clarke CL; Balleine RL; Gurney H
Clin Pharmacol Ther; 2005 Jan; 77(1):33-42. PubMed ID: 15637529
[TBL] [Abstract][Full Text] [Related]
14. [In vivo monitoring of chemotherapy multidrug resistance (MDR)].
Fraile M
Rev Esp Med Nucl; 1999; 18(1):1-3. PubMed ID: 10383232
[No Abstract] [Full Text] [Related]
15. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy.
Taki J; Sumiya H; Asada N; Ueda Y; Tsuchiya H; Tonami N
J Nucl Med; 1998 Jul; 39(7):1179-84. PubMed ID: 9669390
[TBL] [Abstract][Full Text] [Related]
16. Characterization of P-glycoprotein transport and inhibition in vivo.
Barbarics E; Kronauge JF; Cohen D; Davison A; Jones AG; Croop JM
Cancer Res; 1998 Jan; 58(2):276-82. PubMed ID: 9443405
[TBL] [Abstract][Full Text] [Related]
17. Cationic lipophilic radiotracers for functional imaging of multidrug resistance.
Gomes CM
Curr Radiopharm; 2012 Apr; 5(2):113-23. PubMed ID: 22280111
[TBL] [Abstract][Full Text] [Related]
18. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
Kostakoglu L; Elahi N; Kïratlï P; Ruacan S; Sayek I; Baltalï E; Sungur A; Hayran M; Bekdik CF
J Nucl Med; 1997 Jul; 38(7):1003-8. PubMed ID: 9225779
[TBL] [Abstract][Full Text] [Related]
19. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.
Del Vecchio S; Ciarmiello A; Pace L; Potena MI; Carriero MV; Mainolfi C; Thomas R; D'Aiuto G; Tsuruo T; Salvatore M
J Nucl Med; 1997 Sep; 38(9):1348-51. PubMed ID: 9293785
[TBL] [Abstract][Full Text] [Related]
20. A novel areneisonitrile Tc complex inhibits the transport activity of MDR P-glycoprotein.
Rao VV; Herman LW; Kronauge JF; Piwnica-Worms D
Nucl Med Biol; 1998 Apr; 25(3):225-32. PubMed ID: 9620627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
